H.C. Wainwright analyst Emily Bodnar downgraded SQZ Biotechnologies to Neutral from Buy without a price target. The company’s "sizable" restructuring effort lead the analyst to shift expectations for data next week. The decision to announce a significant restructuring prior to the data announcement likely indicates that the data are not impressive, Bodnar tells investors in a research note. The analyst alsos believe the decision to pause both monotherapy and combination cohorts for the antigen presenting cells platform likely indicates that the data in combination were not materially better than the monotherapy data.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SQZ:
- SQZ Biotechnologies price target lowered to $4 from $16 at Chardan
- SQZ Biotechnologies double-downgraded to Underperform at BofA
- SQZ Biotechnologies announces strategic prioritization, resignation of CEO/CFO
- SQZ Biotechnologies downgraded to Underperform from Buy at BofA
- SQZ Biotechnologies reports Q3 EPS (77c), consensus (83c)